API reference
Rotigotine
- CAS number
- 99755-59-6
- Molecular formula
- C19H25NOS
- Molecular weight
- 315.5 g/mol
About this molecule
Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours. Like other dopamine agonists, rotigotine has been shown to possess antidepressant effects and may be useful in the treatment of depression as well. Rotigotine was developed by Aderis Pharmaceuticals. In 1998 Aderis licensed worldwide development and commercialization rights to Schwarz Pharma of Germany. It was approved by the European Medicines Agency in 2006 and by the FDA in 2007. However, all Neupro patches in the United States and some of Europe were recalled in 2008 due to delivery mechanism issues. Rotigotine has been authorized as a treatment for RLS since August 2008.
Source: DrugBank, via PubChem.
Identifiers
- IUPAC name
- (6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol
- InChIKey
- KFQYTPMOWPVWEJ-INIZCTEOSA-N
- SMILES
- CCCN(CCC1=CC=CS1)[C@H]2CCC3=C(C2)C=CC=C3O
- PubChem CID
- 59227
Also known as
Rotigotine · Neupro · Leganto · SPM 962 · SPM-962 · Rotigotina · rotigotinum · rotigotine, (+--)-
Chemical data on this page is drawn from PubChem (National Library of Medicine) and is provided for identification only. Hanpars does not hold stock of every substance listed; availability, grade, documentation and regulatory status are confirmed per enquiry.
Tell us the grade, the quantity and the market.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.